Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Dot enzyme-linked immunosorbent assay for more reliable staging of patients with human African trypanosomiasis
Journal of Clinical Microbiology, Volume 43, No. 9, Year 2005
Notification
URL copied to clipboard!
Description
Human African trypanosomiasis (HAT) or sleeping sickness is a disease characterized by a hemolymphatic stage 1 followed by a meniegoencephalitic stage 2 which is fatal without specific treatment. Furthermore, due to the toxicity of drugs used to treat stage 2 (mainly melarsoprol) accurate staging is required. Actual criteria employed during field surveys are not sensitive enough for precise staging. Antineurofilament (anti-NF) and antigalactocerebrosides (anti-GalC) antibodies have been identified in cerebrospinal fluid (CSF) as potential markers of central nervous system (CNS) involvement. We describe a dot enzyme-linked immunosorbent assay (dot-ELISA) to detect anti-GalC and anti-NF antibodies and its value in staging. NF- and GalC-dotted nitrocellulose strips were first developed in our laboratory. They were then evaluated in Angola and Central African Republic on 140 CSF samples. Compared to our staging criteria (i.e., CSF cell count ≥ 20 cells/μl, CSF immunoglobulin M concentration ≥ 100 mg/liter, and/or the presence of trypanosomes in the CSF), combined detection of both CSF anti-NF and CSF anti-GalC by dot-ELISA showed 83.2% sensitivity and 100.0% specificity. Dot-ELISA could be a useful test to diagnose CNS involvement in HAT in the less-equipped laboratories or in the field situation and to improve patient treatment. Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Authors & Co-Authors
Courtioux, Bertrand
France, Limoges
Institut D’epidémiologie Neurologique et de Neurologie Tropicale
Bisser, Sylvie
Gabon, Franceville
Centre International de Recherches Medicales de Franceville
M'belesso, Pascal
Central African Republic
Hôpital de L'amitié
Ngoungou, Edgard Brice
France, Limoges
Institut D’epidémiologie Neurologique et de Neurologie Tropicale
Girard, Murielle
France, Limoges
Institut D’epidémiologie Neurologique et de Neurologie Tropicale
Nangouma, Auguste
Central African Republic
Ministère de la Santé Publique
Josénando, Théophile
Angola, Luanda
Instituto de Combate e Controlo Das Tripanossomiases
Jauberteau-Marchan, M. O.
France, Limoges
Homéostasie Cellulaire et Pathologies
Bouteille, Bernard
France, Limoges
Institut D’epidémiologie Neurologique et de Neurologie Tropicale
Statistics
Citations: 29
Authors: 9
Affiliations: 6
Identifiers
Doi:
10.1128/JCM.43.9.4789-4795.2005
ISSN:
00951137
Research Areas
Health System And Policy
Study Design
Cross Sectional Study
Study Locations
Angola
Central African Republic